[输血和铁化在骨髓质疏松症候群中]
1Hôpital Saint-Vincent-de-Paul, service d'hématologie et de thérapie cellulaire, boulevard de Belfort, 59000 Lille, France.
Bulletin du cancer
|August 5, 2023
概括
骨髓质疏松综合征 (MDS) 患者的铁过载 (IO) 是有毒的. 铁化疗 (ICT) 改善了依赖输血的MDS患者的存活率和无事件存活率,血清费里水平至少为1000ng/mL.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 内部医学 内部医学
背景情况:
- 铁过载 (IO) 在患有低风险骨髓质疏松综合征 (MDS) 的老年患者中构成显著的毒性风险,类似于年轻的血病患者.
- 心血管疾病加剧了MDS患者对IO毒性的脆弱性.
- 最近的注册研究表明,在这些患者中,铁化疗 (ICT) 具有生存益处.
研究的目的:
- 评估铁化疗法 (ICT) 对无事件生存 (EFS) 对输血依赖性骨髓质综合征 (MDS) 患者的影响.
- 评估ICT在缓解MDS患者铁过载的毒性影响方面的有效性.
主要方法:
- 这项研究涉及一项随机试验 (Telesto研究),评估在依赖输血的MDS患者中的ICT.
- 被纳入的患者血清费里水平至少为1000ng/mL.
- 分析了后续数据,以观察EFS曲线的分离和并发症的时间.
主要成果:
- Telesto研究表明,使用ICT,无事件生存率 (EFS) 得到改善.
- 两年后,EFS曲线分开,表明并发症的发病时间延迟.
- 信息和通信技术的好处逐渐显现,这表明治疗效果的显现缓慢.
结论:
- 铁化疗是一种可行的选择,用于输血依赖的MDS患者,预期寿命至少为两年.
- 这些发现支持使用1000ng/mL的血清费里丁值来启动ICT.
- 需要进一步调查早期启动ICT以持续抑制IO相关的氧化压力,可能包括对低甲基化剂有反应的高风险MDS患者.
相关概念视频
01:22Bone Marrow Sampling and Transplants
360
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
360
02:45Blood Transfusion and Agglutination
10.9K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.9K
01:27Disorders of Erythrocytes
992
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
992
01:14Erythropoiesis
4.4K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.4K